Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / ZYME - Zymeworks Announces Additional Leadership Appointments | Benzinga


ZYME - Zymeworks Announces Additional Leadership Appointments | Benzinga

    • Dr. Jeffrey Smith named Executive Vice President and Chief Medical Officer
    • Dr. John Fann promoted to Senior VP, Process Sciences
    • Seven new Vice Presidents appointed, underscoring commitment to leadership development

    VANCOUVER, British Columbia, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced significant additions to its leadership team. These additions to the leadership team highlight Zymeworks' commitment to nurturing and advancing internal talent to key leadership roles while strengthening the capabilities and experience of the organization.

    "At Zymeworks, we recognize that our greatest asset is our people. Elevating talented individuals is a reflection of their strong performance for the company, our confidence in their abilities and the emphasis we place on cultivating leaders from within. As we continue to grow, their expanded roles will play crucial parts in advancing our ‘5 by 5' development programs into the clinic in 2024 and 2025, planning to develop our ADVANCE preclinical programs into clinical studies by 2027 and helping to form the necessary collaborations and partnerships for our emerging product portfolio," said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.

    Leadership Team

    Dr. Jeffrey Smith has been promoted to Executive Vice President and Chief Medical Officer, where he will play a key role in leading the clinical development of our early-stage programs and overseeing our integrated global early-stage development group.

    Dr. John Fann has been promoted to Senior Vice President, Process Sciences, where he will continue to play a key role in supporting the advancement of our new product candidates from preclinical studies into clinical trials.

    In addition, the following individuals have been appointed to the leadership team:

    • Raquera Brown, Vice President, Quality
    • Bijal Desai, Vice President, Finance & Strategy
    • Lucas Donigian, Vice President, Business & Commercial Development
    • Dr. Lindsey Foulkes, Vice President, Corporate Development
    • Cathie Graham, Vice President, Legal
    • Laura O'Connor, Vice President, Human Resources & DEI
    • Dr. Joe Woolery, Vice President, Early-Stage Development (Americas)

    "These outstanding individuals ...

    Full story available on Benzinga.com

  • Stock Information

    Company Name: Zymeworks Inc.
    Stock Symbol: ZYME
    Market: NYSE
    Website: zymeworks.com

    Menu

    ZYME ZYME Quote ZYME Short ZYME News ZYME Articles ZYME Message Board
    Get ZYME Alerts

    News, Short Squeeze, Breakout and More Instantly...